Trial
NCT01610765
A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Alabama at Birmingham
Collaborators
—
Condition
Herpes Simplex Virus
Intervention
Novel Antiviral Drug
Why stopped
Study terminated because unable to obtain access to study drug for study population.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-07